Last reviewed · How we verify

NCT06765603

Evaluating the Efficacy of the Combination of Multi-zonal Contact Lens and Atropine for Controlling Myopia Progression

Not yet recruiting Phase 2 Last updated 9 January 2025
What this trial tests

Phase 2 trial testing Atropine 0.025% in Myopia in 180 participants. Not yet recruiting.

Timeline
1 February 2025
Primary endpoint
31 December 2028
31 December 2029

Quick facts

Lead sponsorSingapore National Eye Centre
PhasePhase 2
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designsingle group
Maskingquadruple
Primary purposetreatment
Enrollment180
Start date1 February 2025
Primary completion31 December 2028
Estimated completion31 December 2029

Drugs / interventions tested

Conditions studied

Sponsor

Singapore National Eye Centre — full company profile →

Who can join

Adults 7 to 13, any sex, with Myopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to explore efficacy of combination Atropine and multifocal CL. Randomized Control Trial including 4 arms: Atropine / multizonal CL; Atropine/ SV CL, Placebo drop/ multizonal CL; Placebo drop/ SV CL. Followed over 1 year with outcome measure of change in spherical equivalent and axial length.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Myopia

Currently open trials in the same condition.

Other Singapore National Eye Centre trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06765603.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing